We are live on ! Find out more
NVS icon

Novartis

1,312 hedge funds and large institutions have $15.2B invested in Novartis in 2024 Q3 according to their latest regulatory filings, with 100 funds opening new positions, 415 increasing their positions, 480 reducing their positions, and 79 closing their positions.

New
Increased
Maintained
Reduced
Closed

27% more first-time investments, than exits

New positions opened: 100 | Existing positions closed: 79

4% more capital invested

Capital invested by funds: $14.7B → $15.2B (+$539M)

0% more funds holding

Funds holding: 1,3071,312 (+5)

0.25% less ownership

Funds ownership: 6.29%6.03% (-0.25%)

13% less funds holding in top 10

Funds holding in top 10: 1513 (-2)

14% less repeat investments, than reductions

Existing positions increased: 415 | Existing positions reduced: 480

42% less call options, than puts

Call options by funds: $171M | Put options by funds: $294M

Holders
1,312
Holders Change
+5
Holders Change %
+0.38%
% of All Funds
18.84%
Holding in Top 10
13
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-13.33%
% of All Funds
0.19%
New
100
Increased
415
Reduced
480
Closed
79
Calls
$171M
Puts
$294M
Net Calls
-$123M
Net Calls Change
-$96.4M
Name Holding Trade Value Shares
Change
Change in
Stake
Natixis Advisors
26
Natixis Advisors
Massachusetts
$108M +$2.99M +26,317 +3%
Capital Research Global Investors
27
Capital Research Global Investors
California
$104M +$148K +1,307 +0.1%
EARNEST Partners
28
EARNEST Partners
Georgia
$93.1M -$15.9K -140 -0%
Bank of Montreal
29
Bank of Montreal
Ontario, Canada
$90.3M +$14M +123,077 +19%
Bank of New York Mellon
30
Bank of New York Mellon
New York
$87.5M -$130M -1,144,031 -60%
Truist Financial
31
Truist Financial
North Carolina
$85.6M -$663K -5,842 -0.8%
Grantham, Mayo, Van Otterloo & Co (GMO)
32
Grantham, Mayo, Van Otterloo & Co (GMO)
Massachusetts
$76.5M -$13M -114,662 -15%
JWBC
33
John W. Bristol & Co
New York
$71.7M -$138K -1,214 -0.2%
Royal Bank of Canada
34
Royal Bank of Canada
Ontario, Canada
$67.4M -$5.98M -52,742 -8%
Corient Private Wealth
35
Corient Private Wealth
Florida
$66.7M -$107K -941 -0.2%
CCMG
36
Clark Capital Management Group
Pennsylvania
$65.9M +$9.21M +81,156 +17%
RJA
37
Raymond James & Associates
Florida
$59.6M -$2.09M -18,426 -3%
SEI Investments
38
SEI Investments
Pennsylvania
$59.3M -$6.19M -54,586 -10%
First Trust Advisors
39
First Trust Advisors
Illinois
$59M +$5.13M +45,219 +10%
American Century Companies
40
American Century Companies
Missouri
$58.6M +$1.93M +16,974 +3%
HPG
41
Harvest Portfolios Group
Ontario, Canada
$57.3M -$2.23M -19,676 -4%
CIBC Private Wealth Group
42
CIBC Private Wealth Group
Georgia
$56.7M +$429K +3,783 +0.8%
DADC
43
D.A. Davidson & Co
Montana
$56M -$561K -4,942 -1%
LPL Financial
44
LPL Financial
California
$49.6M +$3.35M +29,495 +7%
Ameriprise
45
Ameriprise
Minnesota
$48.9M -$2.59M -22,846 -5%
TH
46
TCTC Holdings
Texas
$45.4M -$57.6K -508 -0.1%
TAM
47
Todd Asset Management
Kentucky
$45.4M -$269K -2,373 -0.6%
NW
48
NewEdge Wealth
Pennsylvania
$45.1M +$3.2M +28,190 +8%
Pacer Advisors
49
Pacer Advisors
Pennsylvania
$44.3M +$1.13M +9,934 +3%
MIS
50
Morningstar Investment Services
Illinois
$43.5M +$104K +918 +0.2%

NVS Hedge Fund Activity: Q3 2024 in Review

1,312 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Novartis (NVS) for Q3 2024, worth a combined $15.2B — up 3.7% from $14.7B a quarter earlier.

Buyers outnumbered sellers: 100 funds opened new NVS positions and 79 closed out — a net gain of 21 holders — while 415 added to existing stakes and 480 trimmed.

The largest buyer was Dimensional Fund Advisors, adding an estimated $77.8M. The largest seller was Magnetar Financial, exiting entirely with an estimated $139M sold.

  • 1,312 institutional investors held Novartis (NVS) as of Q3 2024, up from 1,307 in Q2 2024.
  • Funds reported $15.2B of Novartis stock for Q3 2024, up 3.7% quarter-over-quarter.
  • 100 funds opened new Novartis positions in Q3 2024 and 79 closed out, a net change of +21 holders.
  • The largest Novartis buyer in Q3 2024 was Dimensional Fund Advisors, an estimated $77.8M added.
  • The largest Novartis seller in Q3 2024 was Magnetar Financial, an estimated $139M sold.

Based on aggregated 13F filings for Q3 2024.